natgillin/translations-raw huggingface dataset:
In so far as the used analytical procedure makes it possible, the analytical results shall contain the levels of the individual PCDD/PCDF and dioxin-like PCB congeners and be reported as lower-bound, upper-bound and medium-bound in order to include a maximum of information in the reporting of the results and thereby enabling the interpretation of the results according to specific requirements.
Kolikor uporabljeni analitski postopki to omogočajo, analitski rezultati vsebujejo vrednosti posameznih PCDD/PCDF in kongenerov dioksinom podobnih PCB, sporočijo pa se na spodnji meji, zgornji meji in srednji meji, da se v poročilo o rezultatih vključi kar največ podatkov in tako omogoči razlaga rezultatov glede na posebne zahteve.
The report shall include the method used for extraction of PCDD/PCDFs, dioxin-like PCBs and lipids.
Poročilo vključuje tudi metodo, uporabljeno za ekstrakcijo PCDD/PCDF, dioksinom podobnih PCB in maščob.
The recoveries of the individual internal standards shall be made available in case the recoveries are outside the range referred to in point 7.2.5, in case the maximum level is exceeded and in other cases upon request.
Izkoristki posameznih notranjih standardov so na voljo, če so zunaj območja iz točke 7.2.5, če je presežena mejna vrednost in na zahtevo tudi v drugih primerih.
As the uncertainty of measurement is to be taken into account when deciding about the compliance of a sample, this parameter shall be made available.
Ker je treba pri odločanju o skladnosti vzorca upoštevati merilno negotovost, je ta parameter na voljo.
Thus, analytical results shall be reported as x +/– U whereby x is the analytical result and U is the expanded measurement uncertainty using a coverage factor of 2 which gives a level of confidence of approximately 95 %.
Rezultat analize je zato izražen kot x +/– U, pri čemer je x rezultat analize, U pa razširjena merilna negotovost, kar pri faktorju zajetja 2 pomeni približno 95-odstotno stopnjo zaupanja.
In the case of a separate determination of PCDD/PCDFs and dioxin-like-PCBs, the sum of the estimated expanded uncertainty of the separate analytical results of PCDD/PCDFs and dioxin-like PCBs shall be used for the sum of PCDD/Fs and dioxin-like PCBs.
Pri ločenem preskušanju za določitev PCDD/PCDF in dioksinom podobnih PCB je treba vsoto ocenjene razširjene negotovosti ločenih rezultatov analize vsebnosti PCDD/PCDF in dioksinu podobnih PCB uporabiti za vsoto PCDD/PCDF in dioksinom podobnih PCB.
If the uncertainty of measurement is taken into account by applying CCα (as described in point 2.2), this parameter shall be reported.
Če se merilna negotovost upošteva z uporabo CCα (kot je opisana v točki 2.2), se navede ta parameter.
The results shall be expressed in the same units and with at least the same number of significant figures as the maximum levels laid down in Directive 2002/32/EC.
Rezultati analize mejne vrednosti se izrazijo z istimi enotami in zaokrožijo (vsaj) na enako število decimalnih mest, kakor je določeno v Direktivi (ES) 2002/32/ES.
The result of the screening shall be expressed as “compliant” or “suspected to be non-compliant” (“suspected”).
Rezultat presejanja se navede kot „skladen“ ali „s sumom na neskladnost“ („sumljiv“).
In addition, a result for PCDD/PCDF and/or dioxin-like PCBs expressed in BEQ, and not TEQ, may be given.
Poleg tega se lahko navede rezultat za PCDD/PCDF in/ali dioksinom podobne PCB, izražen v BEQ in ne v TEQ.
If measurement uncertainty on the calculated BEQ level is given, for example as standard deviation, it shall be based on at least a triplicate analysis of the sample, including extraction, clean up and determination of the test response.
Če se pri izračunani vrednosti BEQ navede merilna negotovost, na primer kot standardni odmik, temelji na vsaj trikratni analizi vzorca, vključno z ekstrakcijo, čiščenjem in določitvijo odzivnosti preskusa.
Samples with a response below the reporting limit shall be expressed as “lower than the reporting limit”.
Za vzorce, pri katerih je odziv pod pragom poročanja, se navede, da so „pod pragom poročanja“.
For each type of sample matrix, the report shall mention the level of interest on which the evaluation is based.
Za vsako vrsto vzorca matrice se v poročilu navede predpisana vrednost, na kateri temelji ocena.
The report shall mention the type of the test applied, the basic test principle and the kind of calibration.
V poročilu se navedejo vrsta uporabljenega preskusa, osnovno načelo preskusa in vrsta umerjanja.
Sample preparation and requirements for methods of analysis used in official control of the levels of non-dioxin-like PCBs (PCB # 28, 52, 101, 138, 153, 180)
Priprava vzorca in zahteve za analitske metode za uradni nadzor vsebnosti dioksinom nepodobnih PCB (PCB # 28, 52, 101, 138, 153, 180)
Gas chromatography/Electron capture detection (GC/ECD), GC/LRMS, GC/MS-MS, GC/HRMS or equivalent methods.
Plinska kromatografija / detekcija zajetja elektronov (GC/ECD), GC/LRMS, GC/MS-MS, GC/HRMS ali enakovredne metode.
Relative retention time in relation to internal standards or reference standards (acceptable deviation of +/– 0,25 %).
Relativni retencijski čas glede na interne standarde ali referenčne standarde (sprejemljivi odmik +/– 0,25 %).
Requirements for GC/MS techniques
Zahteve za tehnike GC/MS
two specific ions for HRMS;
dveh specifičnih ionov za HRMS;
two specific ions of m/z > 200 or three specific ions of m/z > 100 for LRMS;
dveh specifičnih ionov z m/z > 200 ali treh specifičnih ionov z m/z > 100 za LRMS;
Relative deviation of abundance ratio of selected mass fragments from theoretical abundance or calibration standard for target ion (most abundant ion monitored) and qualifier ion(s):
relativni odmik intenzitete izbranih masnih fragmentov od teoretičnega odziva ali umeritveni standard za izbrani ciljni ion (to je ion z najmočnejšim odzivom, ki se spremlja) in potrditvene ione:
Requirements for GC/ECD techniques
Zahteve za tehnike GC/ECD
Results exceeding the tolerance shall be confirmed with two GC columns with stationary phases of different polarity.
Rezultati, ki presegajo dopustne meje, se potrdijo z dvema kolonama GC s stacionarnimi fazami različne polarnosti.
The performance of the method shall be validated in the range of the level of interest (0,5 to 2 times the level of interest) with an acceptable coefficient of variation for repeated analysis (see requirements for intermediate precision in point 8).
Zmogljivost metode se validira v območju predpisane vrednosti (0,5-kratna do 2-kratna predpisana vrednost) s sprejemljivim koeficientom variacije za ponovljene analize (glej zahteve za srednjo natančnost v točki 8).
The blank values shall not be higher than 30 % of the level of contamination corresponding to the maximum level.
Slepe vrednosti ne presegajo 30-odstotne ravni kontaminacije, ki ustreza mejni vrednosti.
Regular blank controls, analysis of spiked samples, quality control samples, participation in inter-laboratory studies on relevant matrices.
Redne slepe kontrole, analize vzorcev z dodatkom, analize kontrolnih vzorcev, sodelovanje v medlaboratorijskih študijah z različnimi matricami vzorcev.
Suitable internal standards with physico-chemical properties comparable to analytes of interest shall be used.
Uporabljajo se primerni interni standardi s fizikalno-kemijskimi lastnostmi, primerljivimi s predpisanimi analiti.
Addition to products (before extraction and clean-up process).
dodajanje vzorcem izdelkov (pred ekstrakcijo in čiščenjem).
results shall be corrected for recoveries of internal standards;
rezultati se popravijo glede izkoristka internih standardov;
recoveries of isotope-labelled internal standards shall be between 50 and 120 %;
izkoristek izotopsko označenih internih standardov je med 50 in 120 %;
lower or higher recoveries for individual congeners with a contribution to the sum of the six indicator PCBs below 10 % are acceptable.
sprejemljivi so manjši ali večji izkoristki za posamezne kongenere z manj kot 10-odstotnim prispevkom k vsoti šestih indikatorskih PCB.
recovery of internal standard(s) shall be controlled for every sample;
izkoristek internih standardov se nadzoruje za vsak vzorec;
recoveries of internal standard(s) shall be between 60 and 120 %;
izkoristek internih standardov je med 60 in 120 %;
results shall be corrected for recoveries of internal standards.
rezultati se popravijo glede izkoristka internih standardov.
Recoveries for these congeners shall be considered acceptable, if they are between 70 and 120 %.
Izkoristek teh kongenerov se šteje za sprejemljiv, če je med 70 in 120 %.
Performance characteristics: criteria for the sum of the six indicator PCBs at the level of interest
Značilnosti zmogljivosti metode: merila za vsoto šestih indikatorskih PCB pri predpisani vrednosti
Intermediate precision (RSD%)
Srednja natančnost (RSD %)
Difference between upper- and lower-bound calculation
Razlika med izračunom na zgornji in spodnji meji
In so far as the used analytical procedure makes it possible, the analytical results shall contain the levels of the individual PCB congeners and be reported as lower-bound, upper-bound and medium-bound in order to include a maximum of information in the reporting of the results and thereby enabling the interpretation of the results according to specific requirements.
Če uporabljeni analitski postopki to omogočajo, analitski rezultati vsebujejo vrednosti posameznih kongenerov PCB in se navajajo na spodnji meji, zgornji meji in srednji meji, da se v poročilo o rezultatih vključi kar največ podatkov in tako omogoči razlago rezultatov glede na posebne zahteve.
The report shall include the method used for extraction of PCBs and lipids.
Poročilo vključuje metodo, uporabljeno za ekstrakcijo PCB in maščob.
The recoveries of the individual internal standards shall be made available in case the recoveries are outside the range referred to in point 6, in case the maximum level is exceeded and in other cases upon request.
Izkoristki posameznih notranjih standardov so na voljo, če so zunaj območja iz točke 6, če je presežena mejna vrednost in na zahtevo tudi v drugih primerih.
As the uncertainty of measurement is to be taken into account when deciding about the compliance of a sample, this parameter shall also be made available.
Ker je treba pri odločanju o skladnosti vzorca upoštevati merilno negotovost, mora biti na voljo tudi ta parameter.
If the uncertainty of measurement is taken into account by applying CCα (as described in point 2.1 of Chapter I), this parameter shall be reported.
Če se merilna negotovost upošteva z uporabo CCα (kot je opisana v točki 2.1 poglavja I), se navede ta parameter.
The results shall be expressed in the same units and with at least the same number of significant figures as the maximum levels laid down in Directive 2002/32/EC.’
Rezultati analize mejne vrednosti se izrazijo z istimi enotami in zaokrožijo (vsaj) na enako število decimalnih mest, kakor je določeno v Direktivi (ES) 2002/32/ES.“
The concept of “upper-bound” requires using the limit of quantification for the contribution of each non-quantified congener.
Pojem „na zgornji meji“ zahteva, da se za izračun prispevka vsakega kongenera, ki ni določen, uporablja vrednost meje določanja.
The concept of “lower-bound” requires using zero for the contribution of each non-quantified congener.
Pojem „na spodnji meji“ zahteva, da se za izračun prispevka vsakega kongenera, ki ni določen, uporablja vrednost nič.
The concept of “medium-bound” requires using half of the limit of quantification calculating the contribution of each non-quantified congener.
Pojem „na srednji meji“ zahteva, da se za izračun prispevka vsakega kongenera, ki ni določen, uporablja polovična vrednost meje določanja.
In case the analysis is performed in the frame of a contamination incident, confirmation by duplicate analysis might be omitted in case the samples selected for analysis are through traceability linked to the contamination incident.
Če se analiza izvaja pri kontaminaciji, se lahko izpusti potrjevanje z dvakratno analizo, če so vzorci, izbrani za analizo, s sledljivostjo povezani s kontaminacijo.
The concept of “upper-bound” requires using the limit of quantification for the contribution of each non-quantified congener to the toxic equivalent (TEQ).
Pojem „na zgornji meji“ zahteva, da se za izračun prispevka k toksičnemu ekvivalentu (TEQ) vsakega kongenera, ki ni določen, uporablja vrednost meje določanja.
Adapted to PCDD/Fs and dioxin-like compounds from “Guidelines for the validation of screening methods for residues of veterinary medicines”, EU Reference Laboratories (EURLs) for residues of veterinary medicines and contaminants in food of animal origin in Fougères, Berlin and Bilthoven, 20/1/2010, http://ec.europa.eu/food/food/chemicalsafety/residues/lab_analysis_en.htm
Prilagojeno PCDD/F in dioksinom podobnim spojinam iz „Smernic za validacijo presejalnih metod za ostanke zdravil za uporabo v veterinarski medicini“ ( Guidelines for the validation of screening methods for residues of veterinary medicines), referenčni laboratoriji EU za ostanke zdravil in kontaminantov v živilih živalskega izvora za uporabo v veterinarski medicini v Fougeresu, Berlinu in Bilthovnu, 20.1.2010, http://ec.europa.eu/food/food/chemicalsafety/residues/lab_analysis_en.htm.
Bioanalytical methods are not specific to those congeners included in the TEF scheme.
Bioanalitske metode niso specifične za določanje spojin kongenerov vključenih v sistem TEF.
With respect to the maximum levels.
glede na mejne vrednosti
Current requirements are based on the TEFs published in: M. Van den Berg et al., Toxicol Sci 93 (2), 223–241 (2006).
Sedanje zahteve temeljijo na TEF, ki so objavljeni v: M. Van den Berg in sod., Toxicol Sci 93 (2), str. 223–241 (2006).
Sufficient number of mass fragments with relative intensity > 10 % available, therefore not recommendable to use qualifier ion(s) with a relative intensity of less than 10 % compared to the target ion.
Na voljo mora biti zadostno število masnih fragmentov z relativno intenziteto > 10 %, drugače ni priporočljiva uporaba potrditvenih ionov z relativnim odzivom pod 10 % glede na ciljni ion.
When calculating the concentrations from a TCDD calibration curve, values at the lower and higher end of the curve will show a high variation (high coefficient of variation (CV)).
Kadar se koncentracije izračunajo iz umeritvene krivulje TCDD, vrednosti na spodnjem in zgornjem koncu krivulje pokažejo veliko razliko (visok koeficient variacije, KV).
The lower end of the working range (reporting limit) shall be set at least by a factor of 3 above the procedure blanks.
Spodnji del delovnega območja (prag poročanja) se določi najmanj trikrat višje kot postopek s slepimi vzorci.
Cut-off values (see point 8.3) shall be well within the working range.
Izločitvene vrednosti (glej točko 8.3) so znotraj delovnega območja.
The relationship between bioanalytical results in BEQ and GC/HRMS results in TEQ shall be established, for example by matrix-matched calibration experiments, involving reference samples spiked at 0, 0,5 ×, 1 × and 2 × maximum level, with 6 repetitions on each level (n = 24).
Določi se razmerje med bioanalitskimi rezultati v BEQ in rezultati GC/HRMS v TEQ, na primer z umeritvenimi preskusi v matrici, ki vključujejo referenčne vzorce z dodatkom pri 0, 0,5-kratni, 1-kratni in 2-kratni mejni vrednosti s šestimi ponovitvami na vsaki ravni (n = 24).
Correction factors (blank and recovery) may be estimated from this relationship but shall be checked in accordance with point 8.2.2.
Na podlagi tega razmerja se lahko ocenijo korekcijski faktorji (za slepe vrednosti in izkoristek), vendar se preverijo v skladu s točko 8.2.2.
Cut-off values shall be established for decisions over sample compliance with maximum levels or for the control of action thresholds, if relevant, with the respective levels of interest set for either PCDD/PCDFs and dioxin-like PCBs alone, or for the sum of PCDD/PCDFs and dioxin-like PCBs.
Izločitvene vrednosti se določijo za sprejetje odločitev o skladnosti vzorca z mejnimi vrednostmi ali za nadzor pragov ukrepanja, če je to relevantno, glede na zadevne predpisane vrednosti, določene posebej za PCDD/PCDF in za dioksinom podobne PCB ali za vsoto PCDD/PCDF in dioksinom podobnih PCB.
Table of TEF (= toxic equivalency factors) for dioxins, furans and dioxin-like PCBs:WHO-TEFs for human risk assessment based on the conclusions of the World Health Organisation (WHO) – International Programme on Chemical Safety (IPCS) expert meeting which was held in Geneva in June 2005 (Martin van den Berg et al., The 2005 World Health Organisation Re-evaluation of Human and Mammalian Toxic Equivalency Factors for Dioxins and Dioxin-like Compounds. Toxicological Sciences 93(2), 223–241 (2006)).Abbreviations used: “T” = tetra; “Pe” = penta; “Hx” = hexa; “Hp” = hepta; “O” = octa; “CDD” = chlorodibenzodioxin; “CDF” = chlorodibenzofuran; “CB” = chlorobiphenyl.
Razpredelnica TEF (faktorjev toksične ekvivalentnosti) za dioksine, furane in dioksinom podobne PCB:Faktorji toksične ekvivalentnosti (TEF) Svetovne zdravstvene organizacije (SZO) za oceno tveganja za ljudi, ki temeljijo na sklepih Svetovne zdravstvene organizacije – strokovnega srečanja Mednarodnega programa za kemijsko varnost (IPCS) junija 2005 v Ženevi (Martin van den Berg in sod., Ponovna ocena faktorjev toksične ekvivalentnosti za dioksine in dioksinom podobne spojine pri ljudeh in sesalcih, Svetovna zdravstvena organizacija, 2005 (The 2005 World Health Organization Re-evaluation of Human and Mammalian Toxic Equivalency Factors for Dioxins and Dioxin-like Compounds). Toxicological Sciences 93(2), str. 223–241 (2006)).Uporabljene okrajšave: „T“ = tetra; „Pe“ = penta; „Hx“ = heksa; „Hp“ = hepta; „O“ = okta; „CDD“ = klorodibenzodioksin; „CDF“ = klorodibenzofuran; „CB“ = klorobifenil.
CongenerTEF valueDibenzo-p-dioxins (PCDDs) and Dibenzo-p-furans (PCDFs)2,3,7,8-TCDD11,2,3,7,8-PeCDD11,2,3,4,7,8-HxCDD0,11,2,3,6,7,8-HxCDD0,11,2,3,7,8,9-HxCDD0,11,2,3,4,6,7,8-HpCDD0,01OCDD0,00032,3,7,8-TCDF0,11,2,3,7,8-PeCDF0,032,3,4,7,8-PeCDF0,31,2,3,4,7,8-HxCDF0,11,2,3,6,7,8-HxCDF0,11,2,3,7,8,9-HxCDF0,12,3,4,6,7,8-HxCDF0,11,2,3,4,6,7,8-HpCDF0,011,2,3,4,7,8,9-HpCDF0,01OCDF0,0003“Dioxin-like” PCBs Non-ortho PCBs + Mono-ortho PCBs Non-ortho PCBsPCB 770,0001PCB 810,0003PCB 1260,1PCB 1690,03Mono-ortho PCBsPCB 1050,00003PCB 1140,00003PCB 1180,00003PCB 1230,00003PCB 1560,00003PCB 1570,00003PCB 1670,00003PCB 1890,00003
KongenerVrednost faktorja toksične ekvivalentnosti (TEF)Dibenzo-p-dioksini („PCDD“) in dibenzo-p-furani ( „PCDF“) 2,3,7,8-TCDD11,2,3,7,8-PeCDD11,2,3,4,7,8-HxCDD0,11,2,3,6,7,8-HxCDD0,11,2,3,7,8,9-HxCDD0,11,2,3,4,6,7,8-HpCDD0,01OCDD0,00032,3,7,8-TCDF0,11,2,3,7,8-PeCDF0,032,3,4,7,8-PeCDF0,31,2,3,4,7,8-HxCDF0,11,2,3,6,7,8-HxCDF0,11,2,3,7,8,9-HxCDF0,12,3,4,6,7,8-HxCDF0,11,2,3,4,6,7,8-HpCDF0,011,2,3,4,7,8,9-HpCDF0,01OCDF0,0003„Dioksinom podobni“ neorto PCB + monoorto PCB Neorto PCBPCB 770,0001PCB 810,0003PCB 1260,1PCB 1690,03Monoorto PCBPCB 1050,00003PCB 1140,00003PCB 1180,00003PCB 1230,00003PCB 1560,00003PCB 1570,00003PCB 1670,00003PCB 1890,00003
Gas chromatographic separation of all six indicator PCBs (PCB 28, PCB 52, PCB 101, PCB 138, PCB 153 and PCB 180) from interfering substances, especially co-eluting PCBs, in particular if levels of samples are in the range of legal limits and non-compliance is to be confirmed. Note:
Plinsko kromatografsko ločevanje vseh šestih indikatorskih PCB (PCB 28, PCB 52, PCB 101, PCB 138, PCB 153 in PCB 180) od motečih snovi, zlasti sočasno eluiranih PCB, še posebej če so vzorci v območju zakonsko dovoljenih mej in je treba potrditi neskladnost.
Congeners often found to co-elute are for example PCB 28/31, PCB 52/69 and PCB 138/163/164. For GC/MS also possible interferences from fragments of higher chlorinated congeners shall be considered.
[Kongeneri, za katere je pogosto ugotovljeno, da se sočasno eluirajo, so na primer PCB 28/31, PCB 52/69 in PCB 138/163/164. Pri GC/MS se upoštevajo tudi mogoči moteči vplivi masnih fragmentov višjih kloriranih kongenerov.]
Calculation as mean value of bioanalytical results (in BEQ, corrected for blank and recovery) from multiple analysis of samples (n ≥ 6) contaminated at 2/3 the level of interest, based on the observation that this level will be around the cut-off value determined under point 8.3.1 or point 8.3.2: Figure 1
Izračun kot srednja vrednost bioanalitskih rezultatov (v BEQ, s popravkom slepih vrednosti in izkoristka) iz večkratnih analiz vzorcev (n ≥ 6), kontaminiranih pri 2/3 predpisane vrednosti, na podlagi ugotovitve, da bo ta vrednost blizu izločitvene vrednosti iz točk 8.3.1 ali 8.3.2:
Commission Implementing Regulation (EU) No 279/2012
Izvedbena uredba Komisije (EU) št. 279/2012
Commission Implementing Regulation (EU) No 280/2012
Izvedbena uredba Komisije (EU) št. 280/2012
Those prices and duties were last amended by Commission Implementing Regulation (EU) No 276/2012 [4].
Navedene cene in uvozne dajatve so bile nazadnje spremenjene z Izvedbeno uredbo Komisije (EU) št. 276/2012 [4].
OJ L 90, 28.3.2012, p. 19.
UL L 90, 28.3.2012, str. 19.
Amended representative prices and additional import duties applicable to white sugar, raw sugar and products covered by CN code 17029095 from 29 March 2012
Spremenjene reprezentativne cene in dodatne uvozne dajatve za beli in surovi sladkor ter proizvode z oznako KN 17029095, ki se uporabljajo od 29. marca 2012
Commission Implementing Regulation (EU) No 282/2012
Izvedbena uredba Komisije (EU) št. 282/2012
laying down common detailed rules for the application of the system of securities for agricultural products
o skupnih podrobnih pravilih za uporabo sistema varščin za kmetijske proizvode
Having regard to Council Regulation (EC) No 1234/2007 of 22 October 2007 establishing a common organisation of agricultural markets and on specific provisions for certain agricultural products (Single CMO Regulation) [1], and in particular Article 43(a), (d), (f) and (j), Article 47(2), Article 134, Article 143(b), Article 148, Article 161(3), Article 171 and Article 172(2),
ob upoštevanju Uredbe Sveta (ES) št. 1234/2007 z dne 22. oktobra 2007 o vzpostavitvi skupne ureditve kmetijskih trgov in o posebnih določbah za nekatere kmetijske proizvode („Uredba o enotni SUT“) [1] in zlasti člena 43(a), (d), (f) in (j), člena 47(2), člena 134, člena 143(b), člena 148, člena 161(3), člena 171 in člena 172(2) Uredbe,
Having regard to Council Regulation (EC) No 104/2000 of 17 December 1999 on the common organisation of the markets in fishery and aquaculture products [2], and in particular Articles 37 and 38 thereof,
ob upoštevanju Uredbe Sveta (ES) št. 104/2000 z dne 17. decembra 1999 o skupni ureditvi trgov za ribiške proizvode in proizvode iz ribogojstva [2] in zlasti členov 37 in 38 Uredbe,
Having regard to Council Regulation (EC) No 1216/2009 of 30 November 2009 laying down the trade arrangements applicable to certain goods resulting from the processing of agricultural products [3], and in particular Article 4(4), Article 6(4), Article 7(3), and Article 11(4) thereof,
ob upoštevanju Uredbe Sveta (ES) št. 1216/2009 z dne 30. novembra 2009 o trgovinskih režimih za nekatero blago, pridobljeno s predelavo kmetijskih proizvodov [3], in zlasti člena 4(4), člena 6(4), člena 7(3) in člena 11(4) Uredbe,
Having regard to Council Regulation (EC) No 247/2006 of 30 January 2006 laying down specific measures for agriculture in the outermost regions of the Union [4], and in particular Article 25 thereof,
ob upoštevanju Uredbe Sveta (ES) št. 247/2006 z dne 30. januarja 2006 o posebnih ukrepih za kmetijstvo v najbolj oddaljenih regijah Unije [4] in zlasti člena 25 Uredbe,